ZVS 204e
Alternative Names: ZVS-204eLatest Information Update: 28 Aug 2023
At a glance
- Originator Chigenovo
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Rhodopsin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Retinitis pigmentosa
Most Recent Events
- 08 Aug 2023 Preclinical trials in Retinitis pigmentosa in China (Parenteral) (Chigenovo pipeline, August 2023)
- 24 Jun 2022 Chigenovo has patent protection for Rho-adrp gene editing-based methods and compositions in China
- 30 Jul 2020 Chigenovo has patent pending for Rho-adrp gene editing-based methods and compositions in the US